Eva Hoster1, Wolfram Klapper, Olivier Hermine, Hanneke C Kluin-Nelemans, Jan Walewski, Achiel van Hoof, Marek Trneny, Christian H Geisler, Francesco Di Raimondo, Michal Szymczyk, Stephan Stilgenbauer, Catherine Thieblemont, Michael Hallek, Roswitha Forstpointner, Christiane Pott, Vincent Ribrag, Jeanette Doorduijn, Wolfgang Hiddemann, Martin H Dreyling, Michael Unterhalt. 1. Eva Hoster, Roswitha Forstpointner, Wolfgang Hiddemann, Martin H. Dreyling, and Michael Unterhalt, University Hospital Munich; Eva Hoster, University of Munich, Munich; Wolfram Klapper, University of Kiel; Christiane Pott, University Hospital Schleswig-Holstein, Kiel; Michael Hallek, Universität Köln, Köln; Stephan Stilgenbauer, University of Ulm, Ulm, Germany; Olivier Hermine, University Paris Descartes and Université Sorbonne Paris Cité; Catherine Thieblemont, Hôpital Saint Louis, Paris; Vincent Ribrag, Institut Gustave Roussy, Villejuif, France; Hanneke C. Kluin-Nelemans, University of Groningen, Groningen; Jeanette Doorduijn, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Jan Walewski and Michal Szymczyk, Maria Sklodowska-Curie Memorial Institute, Warsaw, Poland; Achiel van Hoof, A. Z. Sint Jan AV, Brugge, Belgium; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Christian H. Geisler, Rigshospitalet, Copenhagen, Denmark; and Francesco Di Raimondo, University of Catania, Italy.
Abstract
PURPOSE: Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. PATIENTS AND METHODS: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). RESULTS: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. CONCLUSION: MIPI was prospectively validated in a large MCL patient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
PURPOSE:Mantle-cell lymphoma (MCL) is a distinct B-cell lymphoma associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as the first prognostic stratification tool specifically directed to patients with MCL. External validation was planned to be performed on the cohort of the two recently completed randomized trials of the European MCL Network. PATIENTS AND METHODS: Data of 958 patients with MCL (median age, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were pooled to assess the prognostic value of MIPI with respect to overall survival (OS) and time to treatment failure (TTF). RESULTS: Five-year OS rates in MIPI low, intermediate, and high-risk groups were 83%, 63%, and 34%, respectively. The hazard ratios for OS of intermediate versus low and high versus intermediate risk patients were 2.1 (95% CI, 1.5 to 2.9) and 2.6 (2.0 to 3.3), respectively. MIPI was similarly prognostic for TTF. All four clinical baseline characteristics constituting the MIPI, age, performance status, lactate dehydrogenase level, and WBC count, were confirmed as independent prognostic factors for OS and TTF. The validity of MIPI was independent of trial cohort and treatment strategy. CONCLUSION:MIPI was prospectively validated in a large MCLpatient cohort homogenously treated according to recognized standards. As reflected in current guidelines, MIPI represents a generally applicable prognostic tool to be used in research as well as in clinical routine, and it can help to develop risk-adapted treatment strategies to further improve clinical outcome in MCL.
Authors: E Hoster; C H Geisler; J Doorduijn; B van der Holt; J Walewski; J Bloehdorn; V Ribrag; G Salles; M Hallek; C Pott; M Szymczyk; A Kolstad; A Laurell; R Räty; M Jerkeman; M Van't Veer; J C Kluin-Nelemans; W Klapper; M Unterhalt; M Dreyling; O Hermine Journal: Leukemia Date: 2015-11-24 Impact factor: 11.528
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Hilka Rauert-Wunderlich; Anja Mottok; David W Scott; Lisa M Rimsza; German Ott; Wolfram Klapper; Michael Unterhalt; Hanneke C Kluin-Nelemans; Olivier Hermine; Sylvia Hartmann; Christoph Thorns; Grzegorz Rymkiewicz; Harald Holte; Martin Dreyling; Eva Hoster; Andreas Rosenwald Journal: Br J Haematol Date: 2018-08-10 Impact factor: 6.998
Authors: Brian G Till; Hongli Li; Steven H Bernstein; Richard I Fisher; W Richard Burack; Lisa M Rimsza; Justin D Floyd; Marco A DaSilva; Dennis F Moore; Olga Pozdnyakova; Sonali M Smith; Michael LeBlanc; Jonathan W Friedberg Journal: Br J Haematol Date: 2015-10-22 Impact factor: 6.998